The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Tools and biomarkers being used for the diagnosis of BPDCN
Muzaffar Qazilbash, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the variable presentation of blastic plasmacytoid dendritic cell neoplasm (BPDCN), emphasizing the importance of skin biopsies, which should be examined by both dermatopathologists and hematopathologists. Dr Qazilbash highlights the comprehensive diagnostic approach, including bone marrow biopsies, cytogenetics, molecular markers, and spinal fluid exams, to detect concurrent blood cancers and elucidate specific genetic mutations. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Sanofi, Janssen, Angiocrine; Advisory Board: Sanofi.
